Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

SB, Cohen; Y, Tanaka; X, Mariette; JR, Curtis; EB, Lee; P, Nash; KL, Winthrop; C, Charles-Schoeman; K, Thirunavukkarasu; R, DeMasi; J, Geier; K, Kwok; L, Wang; R, Riese; J, Wollenhaupt

doi:10.1136/annrheumdis-2016-210457

Public

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Shared by NobleBlocks on Jan 31, 2017 • 12:00 AM UTC

Authors:

Cohen SB

Tanaka Y

Mariette X

Abstract

<h4>Objectives</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report an integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA.<h4>Methods</h4>D...

Subject

Tuberculosis

Rheumatoid arthritis

Treatment

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!